Biochips Market - Databook 2025 to 2034

The global biochips market size surpassed USD 41,920 million in 2024 and is predicted to reach around USD 1,38,570 million by 2034, registering a CAGR of 12.7% from 2025 to 2034.

Highlights of the Biochips Market

• North America dominated the global biochips market in 2024.
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By type, the DNA chips segment holds a dominant presence in the biochips market in 2024.
• By type, the lab-on-chip segment is expected to grow at the fastest rate in the market during the forecast period.
• By fabrication technology, the microarrays segment holds a dominant presence in the biochips market in 2024.
• By fabrication technology, the microfluidics segment is expected to grow at the fastest rate in the market during the forecast period.
• By end-user, the biotechnology & pharmaceutical segment holds a dominant presence in the biochips market in 2024.
• By end-user, the academic & research institutes segment is expected to grow at the fastest rate in the market during the forecast period.

Industry Valuation and Growth Rate Projection

Biochips are tiny laboratories that can achieve hundreds or thousands of coincident biochemical reactions, remarkably improving the accuracy and speed of medical diagnostics and research. These innovative apparatuses are changing healthcare by permitting rapid disease detection, customized treatments, and constantly patient monitoring. Biochip holds the potency to offer real-time understanding of biological samples and information. In healthcare, applications consist of medical diagnostics, therapeutic interventions, drug delivery, and biosensing.

Biochips Market: Stats and Figures

• The Israel Innovation Authority will set up the country’s earliest laboratory for biochips and bio-devices, with an entire investment of 113 million Israeli shekels (US$31 million). The project includes collaboration with Beckermus Technologies and Israel Aerospace Industries, with 75 million Israeli shekels (US$20.56 million) supported by the Innovation Authority.

Industry Leader Announcements

• Dr. Peter FitzGerald, Managing Director of Randox Laboratories

“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians.”

“We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows resulting in better outcomes for patients.”

• Stephen P. MacMillan, Chair of the Board of Illumina

"After conducting a robust search process, we are thrilled to have found someone of Jacob's caliber to become chief executive of Illumina and help shape and lead the company into its next phase of growth," said Stephen P. MacMillan, Chair of the Board of Illumina. "Jacob's unique combination of deep technological and commercial experience will be a great addition to Illumina. The Board is excited to work with Jacob. He brings a fresh perspective, a demonstrated track record driving profitable growth, and a strong commitment to create value for all of Illumina's stakeholders. We are confident that under his direction, Illumina can continue to execute on its goals and drive long-term shareholder value."

How AI Has Benefitted the Biochips Market

• Drug development is costly. AI is anticipated to save pharma firms up to 30% on research and development by streamlining tasks such as candidate identification, data analysis, along with the trial simulations.
• AI has improved gene-editing technologies such as CRISPR. It can assist in designing more targeted therapies, decreasing mistakes in genetic modification and creating gene therapies that are more convenient and effective.
• AI permits for more monitored treatments derived on individual genetic profiles. By detecting genomic data, AI assists doctors detect the most effective treatments, improving patient results and decreasing adverse effects.

Geographical Insights

The biochips market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the rapidly growing market. In the Asia Pacific region is projected to be the fastest growing in the market during the forecast period.

North America

North America dominated the global biochips market in 2024. The United States contributes as a major because of a well-known healthcare framework and big biotechnology firms which have been a robust drive to this market. Many of the latest in customized medicines, pharmaceuticals and genomics, generating a need for biochips. Thus, high investment in healthcare-associated technologies and the increasing initiatives from government fields to fund research and innovation have set this region as the strong market leadership.

Europe

Europe is experiencing rapid growth in the biochips market during the forecast period. The growing application of biochips in biomedical and biotechnology sectors is rapidly boosting the requirement for biochips in Europe. The major boosting factor for the market is the growing acceptance of biochips in proteomics and microarrays.

APAC

Asia Pacific (APAC) is projected to be the fastest growing in the market during the forecast period. It is boosted by the stretching healthcare infrastructure and growing incidence of chronic diseases. The region’s diverse healthcare demands, combined with a growing focus on customized medicine, have led to the rising uptake of biochip technologies, mainly in diagnostics for diabetes, cancer, and cardiovascular disorders. As these countries constantly grow economically, biochips are anticipated to play a vital role in changing healthcare delivery.

Recent Developments

• In January 2025, Coherent Corp. reported the start of the latest pin-hole array biochips for medical diagnostics, with a target on gene sequencing applications.
• In April 2024, Boston Micro Fabrication (BMF) proudly started BMF Biotechnology Inc. is committed to generating and commercializing innovative BioChips via cultivating large-scale tissues in vitro, assisting speed up the latest drug and cosmetic development.
• In March 2024, BrainRap Artificial Intelligence (BRAI) and IndyGeneUS are set to combine in a historic acquisition, identifying a new chapter at the cutting edge of AI innovation and medical science. With IndyGeneUS contributing the strategic move, this merger builds a pioneering, black-owned establishment in neuroscience hardware, deep learning, pharmaceuticals, and AI.

Competitive Landscape

The biochips market is marked to witness substantial expansion; however, it is vital to understand the developing impediments constituted by factors like the existence of alternative technologies and suppression inherent in lab-on-chip apparatus. These parts, among others, could produce difficulties and potentially restrict the overall market growth. The presence of alternative technologies may establish competition and involve differentiation methods to manage market share.

• Company Name: GE HealthCare
• Year of Incorporation: 1994
• Headquarters: Chicago, Illinois, United States

GE Healthcare functions within a greatly competitive company which is continuously evolving. With developments in technology and the growing focus on innovation, the firm must navigate via a sophisticated network of competitors to manage its position as a pioneer in the market.

• Company Name: Agilent Technologies, Inc.
• Year of Incorporation: 1999
• Headquarters: Santa Clara, California, United States

Agilent Technologies functions with a strong target on research and development, Agilent has sustained itself as a main manufacturer of the latest solutions for a broad range of industries, ranging from environmental testing to healthcare.

• Company Name: QIAGEN
• Year of Incorporation: 1984
• Headquarters: Hilden, Germany

Qiagen is an effective and ever progressing one, as the firm continues to innovate and accepts to meet the requirements of the market globally. With a target on offering the latest solutions in life sciences, molecular diagnostics, and applied testing, Qiagen meets stiff competition from emerging players and industry giants alike. Moreover, with track evidence of conveying high-quality goods and a dedication to research and development, it wrecks a formidable force in the biotechnology section, composed for constant growth and success.

Annual Revenue: GE HealthCare Technologies Inc vs Agilent Technologies, Inc. vs Qiagen N.V. 2022-24 (Millions of US $)